Related to OncoMethylome to Carry Out MGMT Assay as Part of Roche’s Phase III Avastin Trial in Glioblastoma

• Researchers Find Hypermethylation in Glioblastoma Indicates Earlier Disease Onset but Improved Outcomes
  
• Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research
  
• ImmunoCellular Therapeutics Taps UPenn to Progress Mid-Stage Glioblastoma Candidate
  
• BioInvent and ThromboGenics Earn €10M as Roche Progresses Anticancer Agent
  
• GATC to Sequence Pediatric Brain Tumors for PedBrainTumor Consortium
  
• Roche and Biogen Idec Ditch Phase III RA Program with Ocrelizumab
  
• NCI to Conduct Phase I Study with Immatics' Glioblastoma Vaccine
  
• Myriad Puts Noncancer Pipeline on Hold and Cuts Workforce
  
• Roche’s RoActemra Eases Symptoms of Systemic Juvenile Idiopathic Arthritis in Phase III Study
  
• Roche and IBM Set Sights on $100–1,000 Genome Nanopore Sequencing Platform
  
• Second Phase III Ovarian Cancer Trial Finds Avastin-Chemotherapy Combo Boosts PFS
  
• Roche Gains Qiagen’s PI3K Oncogene for Mutation Assay Development
  
• Exact Sciences Obtains OncoMethylome Biomarkers for Colorectal Cancer Test
  
• Baylor Genome Center to Sequence 5,000 Exomes Using Roche NimbleGen Capture Technology
  
• Roche to Pay Aileron $25M to Tap Into Stapled Peptide Expertise
  
• Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates
  
• Ambry Confirmed as First U.S. CSP for NimbleGen Sequence-Capture Solution
  
• Eurofins to Provide Roche GS Junior for Smaller-Scale Projects
  
• Roche Pays InterMune $175M for Full Global Rights to Phase II-Stage HCV Drug
  
• FDA Clears Herceptin-Chemotherapy Combo for Metastatic Her2+ Gastric Cancer